Evidence map›Paper›PMID 32698829›Full record

ArticleJournal of neuroinflammation2020

Muramyl dipeptide-mediated immunomodulation on monocyte subsets exerts therapeutic effects in a mouse model of Alzheimer's disease.

Adham Fani Maleki, Giulia Cisbani, Marie-Michèle Plante, Paul Préfontaine, Nataly Laflamme, Jean Gosselin, Serge Rivest

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neuroinflammation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Selective Immunomodulatory and Neuroprotective Effects of a NOD2 Receptor Agonist on Mouse Models of Multiple Sclerosis.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2021
    Article
  12. Review
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Adham Fani MalekiNeuroscience Laboratory, CHU de Quebec Research Center and Department of Molecular Medicine, Faculty of Medicine, Laval University, 2705 Laurier Boulevard, Quebec City, QC, G1V 4G2, Canada.
Giulia CisbaniNeuroscience Laboratory, CHU de Quebec Research Center and Department of Molecular Medicine, Faculty of Medicine, Laval University, 2705 Laurier Boulevard, Quebec City, QC, G1V 4G2, Canada.
Marie-Michèle PlanteNeuroscience Laboratory, CHU de Quebec Research Center and Department of Molecular Medicine, Faculty of Medicine, Laval University, 2705 Laurier Boulevard, Quebec City, QC, G1V 4G2, Canada.
Paul PréfontaineNeuroscience Laboratory, CHU de Quebec Research Center and Department of Molecular Medicine, Faculty of Medicine, Laval University, 2705 Laurier Boulevard, Quebec City, QC, G1V 4G2, Canada.
Nataly LaflammeNeuroscience Laboratory, CHU de Quebec Research Center and Department of Molecular Medicine, Faculty of Medicine, Laval University, 2705 Laurier Boulevard, Quebec City, QC, G1V 4G2, Canada.
Jean GosselinLaboratory of Innate Immunity, CHU of Quebec Research Center and Department of Molecular Medicine, Faculty of Medicine, Laval University, 2705 Laurier Boulevard, Quebec City, QC, G1V 4G2, Canada.
Serge RivestNeuroscience Laboratory, CHU de Quebec Research Center and Department of Molecular Medicine, Faculty of Medicine, Laval University, 2705 Laurier Boulevard, Quebec City, QC, G1V 4G2, Canada. serge.rivest@crchudequebec.ulaval.ca.
Université Laval · CA

Funding

CIHR 331652
6 · The paper itself

Abstract

backgroundMuramyl dipeptide (MDP) is a component derived from minimal peptidoglycan motif from bacteria, and it is a ligand for the NOD2 receptor. Peripheral administration of MDP converts Ly6C

methodsThree months old APP

resultsMemory tests showed mild to a strong improvement in memory function, increased expression levels of postsynaptic density protein 95 (PSD95), and low-density lipoprotein receptor-related protein 1 (LRP1), which are involved in synaptic plasticity and amyloid-beta (Aβ) elimination, respectively. In addition, we found monocyte chemoattractant protein-1(MCP-1) levels significantly increased, whereas intercellular adhesion molecule-1(ICAM-1) significantly decreased, and microglial marker (Iba1) did not change in the treatment group compared to the control. In parallel, we discovered elevated cyclooxygenase-2 (COX2) expression levels in the treated group, which might be a positive factor for synaptic activity.

conclusionsOur results demonstrate that MDP is beneficial in both the early phase and, to some extent, later phases of the pathology in the mouse model of AD. These data open the way for potential MDP-based medications for AD.

Indexed as

Alzheimer DiseaseImmunomodulationAcetylmuramyl-Alanyl-IsoglutamineAmyloid beta-Protein PrecursorAnimalsBrainDisease Models, AnimalHumansMaleMiceMice, Inbred C57BLMice, TransgenicMonocytesNeuronal PlasticityPresenilin-1Acetylmuramyl-Alanyl-IsoglutamineAmyloid beta-Protein PrecursorAPP protein, humanPresenilin-1PSEN1 protein, humanAlzheimer’s diseaseBrain blood vesselsCerebral amyloid angiopathyImmunotherapyMacrophagesMicrogliaMonocytesNOD2 receptorSynapse

Identifiers

PMID32698829
PMCPMC7376735
OpenAlexW3044953986

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.